Inflectra, a Remicade biosimilar, is set to launch in the US despite patent concerns. Pfizer has decided to take the risk in spite of J&J's patents. They determined that J&J's patent position was not that strong.
http://www.fiercepharma.com/marketi...-inflectra-launch-set-a-biosimilars-precedent
So maybe now we will start to see the prices come down a little. And maybe other biosimilar manufacturers will follow suit.
http://www.fiercepharma.com/marketi...-inflectra-launch-set-a-biosimilars-precedent
So maybe now we will start to see the prices come down a little. And maybe other biosimilar manufacturers will follow suit.
